Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04559-4 In a phase 1 trial evaluating GFH375, an oral, dual on–off binding KRAS G12D inhibitor, in patients with KRASG12D-mutated solid tumors, there was one treatment-related death, while most treatment-related adverse events were low-grade, and encouraging response rates were observed in non-small cell lung cancer and…

We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.

Read the original at nature.com →

More in Health & Medicine

DIPHTHERIA CRISIS: THE IMMUNISATION GAP

PAT ONUKWULI argues for surveillance and a catch-up vaccination in schools and communities An earlier article, “Nigeria’s Immunisation Gap,” warned that vaccine availability must not be mistaken for…

More from Tuesday 15 September →